PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00561327|
Recruitment Status : Unknown
Verified July 2007 by German Heart Institute.
Recruitment status was: Recruiting
First Posted : November 20, 2007
Last Update Posted : November 20, 2007
|Condition or disease||Intervention/treatment|
The losartan metabolite EXP3179 potently induces the activity of the peroxisome proliferator-activated receptor γ (PPAR-γ) as a partial agonist in vitro. PPAR-γ is a nuclear hormone receptor and functions as a regulator of lipid- and glucose metabolism. PPAR-γ ligands improve insulin sensitivity and glucose tolerance, and reduce cardiovascular morbidity and mortality in diabetic patients.
Angiotensin II receptor 1-blocking and PPAR-γ-activating properties of losartan metabolites in patients would markedly improve the pharmacological profile of losartan by combining anti-hypertensive and highly beneficial metabolic actions. We developed the following hypothesis:
- Hypertensive patients chronically treated with losartan exhibit sufficient plasma levels of EXP3179 to activate PPARγ.
- PPARγ target genes are induced in monocytes from losartan-treated patients.
|Study Type :||Observational|
|Study Start Date :||September 2007|
Patients chronically treated with drug losartan
Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
Patients not chronically treated with losartan
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00561327
|Contact: Eckart Fleck, Profemail@example.com|
|Contact: Philipp Stawowy, Drfirstname.lastname@example.org|
|German Heart Institute||Recruiting|
|Berlin, Germany, 13353|
|Contact: Eckart Fleck, Prof +49-30-4593 2400 email@example.com|
|Contact: Philipp Stawowy, Dr +49-30-45932473 firstname.lastname@example.org|
|Principal Investigator: Eckart Fleck, Prof|
|Principal Investigator:||Eckart Fleck, Prof||German Heart Institute|
|Principal Investigator:||Ulrich Kintscher, Prof||Institute of Pharmacology Charite University Medicine Berlin Germany|